Conditional survival in de novo metastatic urothelial Carcinoma

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Pal, Sumanta Kumar ^a   Lin, Yulan Ingrid ^a   Yuh, Bertram ^a   DeWalt, Kara ^a   Kazarian, Austin ^a   Vogelzang, Nicholas ^b   Nelson, Rebecca A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; ETHNICITY; FEMALE; GENDER; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED GROUPS BY MARITAL STATUS; OVERALL SURVIVAL; RELATIVE CONDITIONAL SURVIVAL; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; VERY ELDERLY; CANCER REGISTRY; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; UROLOGIC NEOPLASMS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROGNOSIS; SALVAGE THERAPY; SEER PROGRAM; SURVIVAL RATE; UROLOGIC NEOPLASMS; YOUNG ADULT;

EID: 84943303320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136622     Document Type: Article

References (30)

1. Abida W, Bajorin DF, Rosenberg JE. First-Line Treatment and Prognostic Factors of Metastatic Bladder Cancer for Platinum-Eligible Patients. Hematol Oncol Clin North Am. 2015; doi: 10.1016/j.hoc.2014.10.005
2. Yagoda A, Watson RC, Gonzalez-Vitale JC, Grabstald H, Whitmore WF. Cis-dichlorodiammineplatinum( II) in advanced bladder cancer. Cancer Treat Rep. 1976; 60: 917-923. PMID: 1009522
3. Rossof AH, Talley RW, Stephens R, Thigpen T, Samson MK, Groppe C, et al. Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. Cancer Treat Rep. 63: 1557-1564. PMID: 498155
4. Rossof AH, Coltman CA, Jones SE, Talley RW. Phase II evaluation of cis-dichlorodiammineplatinum( II) in lymphomas: a Southwest Oncology Group Study. Cancer Treat Rep. 63: 1605-1608. PMID: 498159
5. Ostrow S, Egorin MJ, Hahn D, Markus S, Leroy A, Chang P, et al. Cis-dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms. Cancer. 1980; 46: 1715-1721. doi: 10.1002/1097-0142(19801015)46:8〈1715::AID-CNCR2820460802〉3.0.CO;2-HPMID: 7191768
6. Gondo T, Ohori M, Hamada R, Tanaka A, Satake N, Takeuchi H, et al. The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen. Int J Clin Oncol. 2011; 16: 345-351. doi: 10.1007/s10147-011-0188-4 PMID: 21331770
7. Grivas P, Agarwal N, Siefker-Radtke A, Daignault S, Puzanov I, MacVicar GR, et al. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). J Clin Oncol. 2012; 30: abstr 4506.
8. Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier oncology group GU 04-75. J Clin Oncol. 2011; 29: 1525-1530. doi: 10.1200/JCO.2010.31.6067 PMID: 21422406
9. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. The Lancet Oncology. 2011. pp. 211-214. doi: 10.1016/S1470-2045(10)70275-8 PMID: 21376284
10. Bamias A, Moulopoulos LA, Koutras A, Aravantinos G, Fountzilas G, Pectasides D, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma: A phase II study of the hellenic cooperative oncology group. Cancer. 2006; 106: 297-303. doi: 10.1002/cncr.21604 PMID: 16342065
11. Linardou H, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, Deliveliotis C, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatinbased chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004; 64: 479-484. doi: 10.1016/j.urology.2004.04.024 PMID: 15351574
12. Pal SK, Milowsky MI, Plimack ER. Optimizing systemic therapy for bladder cancer. J Natl Compr Canc Netw. 2013; 11: 793-804. PMID: 23847217
13. Bellmunt J, Thèodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009; 27: 4454-4461. doi: 10.1200/JCO.2008.20.5534 PMID: 19687335
14. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. The Lancet Oncology. 2010.pp. 861-870. doi: 10.1016/S1470-2045(10)70086-3 PMID: 20537950
15. Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): A trial of the Eastern Cooperative Oncology Group. Cancer. 2008; 112: 2671-2675. doi: 10.1002/cncr.23503 PMID: 18459175
16. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006 pp. 3451-3457. doi: 10.1200/JCO.2005.03.6699
17. Fechner G, Siener R, Reimann M, Kobalz L, Albers P. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006; 60: 27-31. doi: 10.1111/j.1742-1241.2005.00663.x PMID: 16409425
18. Gitlitz BJ, Baker C, Chapman Y, Allen HJ, Bosserman LD, Patel R, et al. A Phase II Study of Gemcitabine and Docetaxel Therapy in Patients with Advanced Urothelial Carcinoma. Cancer. 2003; 98: 1863-1869. doi: 10.1002/cncr.11726 PMID: 14584068
19. Srinivas S, Harshman LC. A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. Chemotherapy. 2009; 55: 321-326. doi: 10.1159/000230695 PMID: 19641314
20. Galsky MD. Treatment patterns and outcomes in "real world" patients (pts) with metastatic urothelial cancer (UC). J Clin Oncol. 2013; 31: abstr 4525.
21. Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: A population-based study. Lancet Oncol. 2012; 13: 927-935. doi: 10.1016/S1470-2045(12)70285-1 PMID: 22877847
22. Surveillance E, and End Results (SEER) Program (www.seer.cancer.gov)
23. SEER∗Stat Database: Mortality- All COD, Aggregated With State, Total U.S. (1969-2012), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015.
24. Corazziari I, Quinn M, Capocaccia R (2004) Standard cancer patient population for age standardizing survival ratios. Eur J Cancer 40: 2307-2316. PMID: 15454257
25. Surveillance Research Program, National Cancer Institute SEER∗Stat software (www.seer.cancer.gov/seerstat) version 8.1.5.
26. Galsky MD, Moshier E, Krege S, Lin C-C, Hahn N, Ecke T, et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013; 119: 3012-9. doi: 10.1002/cncr.28146 PMID: 23720216
27. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17: 3173-3181. PMID: 10506615
28. Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, et al. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014; 113. doi: 10.1111/bju.12564
29. Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, et al. Conditional survival after radical cystectomy for bladder cancer: Evidence for a patient changing risk profile over time. Eur Urol. 2014; 66: 361-370. doi: 10.1016/j.eururo.2013.09.050 PMID: 24139235
30. Sun M, Abdollah F, Bianchi M, Trinh Q-D, Shariat SF, Jeldres C, et al. Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. Eur J Cancer. 2012; 48: 1503-11. doi: 10.1016/j.ejca.2011.11.024 PMID: 22196034